title: Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1.
abstract: Etravirine is an oral diarylpyrimidine compound, a second-generation human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI) with expanded antiviral activity against NNRTI-resistant HIV-1, to be used in combination therapy for treatment-experienced patients. Compared with first-generation NNRTIs, etravirine has a high genetic barrier to resistance, and is better tolerated without the neuropsychiatric and hepatic side effects of efavirenz and nevirapine, respectively. Its safety profile is comparable to placebo with the exception of rash, which has been mild and self-limited in the great majority of patients. In phase III clinical trials among treatment-experienced patients harboring NNRTI-resistant HIV-1, etravirine in combination with an optimized background regimen (OBR) that included ritonavir-boosted darunavir demonstrated superior antiviral activity than the control OBR. In addition, patients on the etravirine arm had fewer AIDS-defining conditions, hospitalizations, and lower mortality compared with the OBR control arm.
authors.affiliation: Department of Pediatrics, Division of Infectious Diseases, Center for AIDS Research, University of California San Diego School of Medicine and UCSD, Mother, Child and Adolescent HIV Program, Rady Children's Hospital, San Diego, California, USA.
authors.forename: Rolando M
authors.initials: RM
authors.lastname: Viani
references.citation: JAMA. 2008 Aug 6;300(5):555-70
references.pmid: 18677028
references.citation: N Engl J Med. 2005 Dec 1;353(22):2325-34
references.pmid: 16319381
references.citation: AIDS. 2010 Feb 20;24(4):503-14
references.pmid: 20051805
references.citation: J Med Chem. 2005 Mar 24;48(6):1689-96
references.pmid: 15771411
references.citation: Clin Pharmacokinet. 2009;48(4):211-41
references.pmid: 19492868
references.citation: AIDS. 2007 Mar 30;21(6):F1-10
references.pmid: 17413684
references.citation: J Am Chem Soc. 2003 May 21;125(20):6016-7
references.pmid: 12785806
references.citation: Antivir Ther. 2008;13(5):655-61
references.pmid: 18771049
references.citation: J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):545-52
references.pmid: 15793364
references.citation: J Acquir Immune Defic Syndr. 2001 Mar 1;26 Suppl 1:S25-33
references.pmid: 11264999
references.citation: AIDS. 2009 Nov 13;23(17):2289-300
references.pmid: 19710593
references.citation: Lancet. 2003 Jul 5;362(9377):22-9
references.pmid: 12853195
references.citation: Pharmacotherapy. 2008 Oct;28(10):1215-22
references.pmid: 18823217
references.citation: Lancet. 2007 Jul 7;370(9581):29-38
references.pmid: 17617270
references.citation: AIDS. 2008 Nov 12;22(17):2291-302
references.pmid: 18981768
references.citation: AIDS. 2010 Jan 16;24(2):317-9
references.pmid: 20010074
references.citation: J Virol. 2008 Jun;82(11):5510-8
references.pmid: 18353964
references.citation: N Engl J Med. 1998 Mar 26;338(13):853-60
references.pmid: 9516219
references.citation: AIDS. 2003 Dec 5;17(18):F49-54
references.pmid: 14685068
references.citation: Clin Ther. 2010 Feb;32(2):328-37
references.pmid: 20206790
references.citation: AIDS. 2008 Nov 12;22(17):2395-8
references.pmid: 18981781
references.citation: J Infect Dis. 2006 Dec 1;194(11):1505-9
references.pmid: 17083034
references.citation: Antimicrob Agents Chemother. 2008 Dec;52(12):4228-32
references.pmid: 18838586
references.citation: N Engl J Med. 2002 Aug 8;347(6):385-94
references.pmid: 12167680
references.citation: HIV Med. 2008 Nov;9(10):883-96
references.pmid: 18795960
references.citation: Clin Pharmacokinet. 2009;48(9):561-74
references.pmid: 19725591
references.citation: Clin Infect Dis. 2009 Nov 1;49(9):1441-9
references.pmid: 19814627
references.citation: Br J Clin Pharmacol. 2008 Oct;66(4):508-16
references.pmid: 18492125
references.citation: J Med Chem. 2004 May 6;47(10):2550-60
references.pmid: 15115397
references.citation: J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S2-7
references.pmid: 14562852
references.citation: AIDS. 2003 Nov 21;17(17):2487-94
references.pmid: 14600520
references.citation: Antivir Ther. 2009;14(1):103-9
references.pmid: 19320243
references.citation: PLoS Med. 2009 Apr 28;6(4):e1000066
references.pmid: 19399157
references.citation: Antivir Ther. 2008;13(8):1011-7
references.pmid: 19195326
references.citation: Lancet. 2007 Jul 7;370(9581):39-48
references.pmid: 17617271
references.citation: Antimicrob Agents Chemother. 2004 Dec;48(12):4680-6
references.pmid: 15561844
references.citation: Int J Epidemiol. 2007 Oct;36(5):1009-21
references.pmid: 17533166